Copyright
©The Author(s) 2023.
World J Clin Cases. Jul 6, 2023; 11(19): 4553-4566
Published online Jul 6, 2023. doi: 10.12998/wjcc.v11.i19.4553
Published online Jul 6, 2023. doi: 10.12998/wjcc.v11.i19.4553
Figure 6 The docking model of the core active ingredient betulinol with the target proteins.
A: Docking of betulinol to Jun proto-oncogene, AP-1 transcription factor subunit; B: Docking of betulinol to vascular endothelial growth factor; C: Docking of betulinol to tumor protein p53; D: Docking of betulinol to AKT1 serine/threonine kinase 1. JUN: Jun proto-oncogene, AP-1 transcription factor subunit; VEGFA: Vascular endothelial growth factor; TP53: Tumor protein p53; AKT1: AKT serine/threonine kinase 1.
- Citation: Li YJ, Tang DX, Yan HT, Yang B, Yang Z, Long FX. Network pharmacology and molecular docking-based analyses to predict the potential mechanism of Huangqin decoction in treating colorectal cancer. World J Clin Cases 2023; 11(19): 4553-4566
- URL: https://www.wjgnet.com/2307-8960/full/v11/i19/4553.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i19.4553